mbiomics GmbH
Germany
- Munich, Bavaria
- 24/03/2023
- Series A
- $13,945,000
We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life.
- Industry Biotechnology Research
- Website https://mbiomics.com/
- LinkedIn https://www.linkedin.com/company/mbiomics-gmbh/
Related People
Laura FigullaCo Founder
Germany -
Munich, Bavaria
With 15+years of life science entrepreneurial and strategy&transactions consulting experience, including venture capital, M&A, digital transformation and innovation strategy, as well as in-depth industry expertise and strong public relations skills, I am truly passionate about creating company strategies, vision and enabling high-performing teams. My career background allows me to provide strategic, fundraising, and business operations insight for innovative life sciences players, in particular around digital health and biotechnology business models.
SavvyMoney | $225,000,000 | (Oct 28, 2025)
Paygentic | $2,000,000 | (Oct 28, 2025)
Honey Health | $7,800,000 | (Oct 28, 2025)
Natural | $9,800,000 | (Oct 28, 2025)
PodPlay Technologies | $8,000,000 | (Oct 28, 2025)
Seneca | $60,000,000 | (Oct 28, 2025)
Serval | $47,000,000 | (Oct 28, 2025)
Bridge | $5,100,000 | (Oct 28, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
GammaTime | $14,000,000 | (Oct 24, 2025)
Apriority Financial, Inc. | $2,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)